Gsk Announced That The Us Food And Drug Administration (Fda) Has Granted Orphan Drug Designation (Odd) To Benlysta (Belimumab), A B-Cell Inhibiting Monoclonal Antibody, For The Potential Treatment Of Systemic Sclerosis. Gsk Plans To Initiate A Phase Ii/Iii Trial Of Belimumab For Systemic Sclerosis Associated Interstitial Lung Disease (Ssc-Ild) In The First Half Of 2023.With Limited Treatment Options Available For Ssc-Ild, The Orphan Drug Designation Reflects The Need For Further Research And The Potential For Belimumab To Address A Critical Need For People Living With This Debilitating Condition.The Us Fda
